Enantioselective Disposition after Single Dose I.V Administration of Ketorolac in Male Wistar Rats

 

 Permissions and Reprints

Abstract

Ketorolac, a commonly used anti-inflamatory and analgesic agent, was studied in male wistar rats. The plasma samples were analysed using chiral AGP column with UV detection. The experimental data was analysed for probable fit in the compartmental and non-compartmental models using WinNolin software. The data of (+)-R-Ketorolac and (−)-S-Ketorolac was found to fit into the compartmental as well as non compartmental model. There was a difference between the plasma concentrations of (+)-R-Ketorolac and (−)-S-Ketorolac; the plasma concentrations of (+)-R-Ketorolac were higher than those of (−)-S-Ketorolac throughout the time course of the study. The area under the curve (AUC) of time vs. concentration profile of (+)-R-Ketorolac was found to be higher than (−)-S-Ketorolac. Volume of distribution and clearance was found to be higher for (−)-S-Ketorolac.

• References

• 1 Rooks WH, Maloney PJ, Shott LD et al. The analgesic and anti-inflammatory profile of Ketorolac and its tromethamine salt. Drugs Exp Clin Res 1985; 11: 479-492
  PubMedGoogle Scholar
• 2 Pallapies D, Salinger A, Meyer Zum Gottesberge et al. Effects of lysine clonixinate and Ketorolac tromethamine on prostanoid release from various rat organs incubated ex vivo. Life Sci 1995; 57: 83-89
  CrossrefPubMedGoogle Scholar
• 3 Galan-Herrera JF, Poo JL, Maya-Barrios JA et al. Bioavailability of two sublingual formulations of Ketorolac tromethamine 30 mg: A randomized, open-label, single-dose, two-period crossover comparison in healthy Mexican adult volunteers. Clin Ther 2008; 30: 1667-1674
  CrossrefPubMedGoogle Scholar
• 4 Zhang Y, Shaffer A, Portanova J et al. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 1997; 283: 1069-1075
  PubMedGoogle Scholar
• 5 Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors and lessons from the clinic. FASEB J 2004; 18: 790-804
  CrossrefPubMedGoogle Scholar
• 6 Guzman A, Yuste F, Toscana RA et al. Absolute configuration of (-)-5-benzoyl-1, 2-dihydro-3H-pyrrolo [1, 2-alpha] pyrrole-1-carboxylic acid, the active enantiomer of Ketorolac. J Med Chem 1986; 29: 589-591
  CrossrefPubMedGoogle Scholar
• 7 Nagilla R, Deshmukh DD, Copedge KJ et al. The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. J Vet Pharmacol Ther 2009; 32: 49-55
  CrossrefPubMedGoogle Scholar
• 8 Jung D, Mroszczak E, Bynum L. Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol 1988; 35: 423-425
  CrossrefPubMedGoogle Scholar
• 9 Mindy NC, Uwe C, Thomas H et al. Pharmacokinetics of Single-Dose Intravenous Ketorolac in Infants Aged 2–11 Months. Anesth Analg 2011; 112: 655-660
  CrossrefPubMedGoogle Scholar
• 10 Anne ML, Heidi B, Eric D et al. Ketorolac tromethamine: stereo-specific pharmacokinetics and single-dose use in postoperative infants aged 2-6 months. Paediatr Anaesth 2011; 21: 325-334
  CrossrefPubMedGoogle Scholar
• 11 Kauffman RE, Lieh-Lai MW, Uy HG et al. Enantiomer-selective pharmacokinetics and metabolism of ketorolac in children. Clin Pharmacol Ther 1999; 65: 382-388
  CrossrefPubMedGoogle Scholar
• 12 Hamunen K, Maunuksela EL, Sarvela J et al. Stereoselective pharmacokinetics of ketorolac in children, adolescents and adults. Acta Anaesthesiol Scand 1999; 43: 1041-1046
  CrossrefPubMedGoogle Scholar
• 13 Hayball J, Wrobel J, Tamblyn JG et al. The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate. Br J clin Pharmac 1994; 37: 75-78
  CrossrefPubMedGoogle Scholar
• 14 Drover DR, Hammer GB, Anderson BJ. The pharmacokinetics of ketorolac after single postoperative intranasal administration in adolescent patients. Anesth Analg 2012; 114: 1270-1276
  CrossrefPubMedGoogle Scholar
• 15 Pasloske K, Renaud R, Burger J et al. Pharmacokinetics of ketorolac after intravenous and oral single dose administration in dogs. J Vet Pharmacol Ther 1999; 22: 314-319
  CrossrefPubMedGoogle Scholar
• 16 Jamali F, Lovlin R, Corrigan BW et al. Stereospecific pharmacokinetics and toxicodynamics of ketorolac after oral administration of the racemate and optically pure enantiomers to the rat. Chirality 1999; 11: 201-205
  CrossrefPubMedGoogle Scholar
• 17 Nagilla R, Deshmukh DD, Duran SH. Stereoselective pharmacokinetics of ketorolac in calves after a single intravenous and oral dose. J Vet Pharmacol Ther 2007; 30: 437-442
  CrossrefPubMedGoogle Scholar
• 18 Wang M, Liu W, Lu Q. Pharmacokinetic comparison of ketorolac after intracameral, intravitreal, and suprachoroidal administration in rabbits. Neurosurgery. 2012
  PubMedGoogle Scholar
• 19 Nagilla R, Deshmukh DD, Copedge KJ et al. Enantiomeric disposition of ketorolac in goats following administration of a single intravenous and oral dose. J Vet Pharmacol Ther 2009; 32: 49-55
  CrossrefPubMedGoogle Scholar
• 20 Santos Ballesteros Ros et al. Chiral pharmacokinetics of ketorolac in sheep after intravenous and intramuscular administration of the racemate. J Vet Pharmacol Ther 2001; 24: 443-446
  PubMedGoogle Scholar
• 21 Dipanjan G, Ajay K, Sunil KD et al. Liquid Chromatographic tandem mass spectrometric validated method for pharmacokinetic estimation of flecainide in human plasma. Clin Res Regul Aff 2009; 26: 24-36
  CrossrefPubMedGoogle Scholar